Сocarboxylase hydrochloride 50 mg 5 vials

1 ampoule (vial) with powder for the preparation of the injection solution contains:

active substance:

cocarboxylase hydrochloride 50 mg

Cocarboxylase is a coenzyme of thiamine (vitamin B1), in the body is phosphorylated to form mono-, di- and triphosphoric esters, is part of the enzymes that catalyze carboxylation and decarboxylation of alpha-keto acids.

Exogenous vitamin B1 (thiamine) to participate in these processes must be metabolized into cocarboxylase, a finished form of coenzyme, by phosphorylation.

It should be noted that the properties of cocarboxylase are only partially adequate to those of thiamine; cocarboxylase is not used for the prevention and treatment of hypo- and avitaminosis B1.

• Metabolic acidosis,
• hyperglycemic coma and acidosis in diabetes mellitus,
• hepatic and renal failure,
• respiratory acidosis in chronic, cardiopulmonary failure,
• respiratory failure,
• chronic circulatory insufficiency,
• coronary heart disease,
• myocardial infarction and post-infarction cardiosclerosis (as part of complex therapy), acute alcohol poisoning and chronic alcoholism;
• poisoning with thimble preparations, barbiturates,
• intoxication in infectious diseases: diphtheria, scarlet fever, typhus and paratyphoid fever (in complex therapy), peripheral neuritis.

There are no data on the safety of the drug when used by pregnant women.

Due to the insufficient number of studies, the drug should not be prescribed to pregnant and lactating women.

Hypersensitivity to the drug.

Allergic reactions are possible (urticaria, skin itching); with intramuscular administration - hyperemia, skin itching, swelling (at the injection site).

Cocarboxylase enhances the effect of cardiac glycosides and improves their tolerability.

Cocarboxylase is administered intramuscularly.

The dose is set individually, depending on the nature of the disease and the severity of the patient's condition.

Adults: 50-100 mg/day, once, if necessary (diabetic coma) - again in 1-2 hours; then switch to a maintenance dose - 50 mg/day; in case of circulatory insufficiency, 50 mg is administered 2 hours before the use of thimble preparations 2-3 times a day.

Children per day (in 1-2 doses): up to 3 months - 25 mg, from 4 months to 7 years - 25-50 mg, from 8 to 18 years - 50-100 mg

If the dose prescribed by the doctor exceeds, symptoms of overdose may appear in the form of: tachycardia; nausea; vomiting; headache; weakness; fatigue; muscle spasms; disorders of the cardiovascular system; allergic reactions; increased sweating; shortness of breath.

If symptoms of overdose appear, the drug is canceled and mandatory symptomatic treatment is carried out.

Due to the presence of glycocholeic acid as an auxiliary substance, in case of repeated and prolonged administration of the drug in patients with jaundice or severe cholestasis (change in the indicators of laboratory functional tests of the liver), it is necessary to carefully monitor liver function.

The deficiency of one or more vitamins should be corrected by administering the missing vitamin. Cernevit does not contain vitamin K, which can be administered separately if necessary.

After dilution, the drug is stable at a temperature not exceeding 25°C for 24 hours, but it is recommended to use the drug immediately after dilution or store no more than 24 hours at a temperature of 2° to 8°C.

Impact on the ability to drive vehicles and control mechanisms

Since Cernevit is intended for patients receiving parenteral nutrition and in severe and moderate condition, the ability to drive and operate with mechanisms has not been assessed.

Lyophilisate for preparation of solution for intramuscular injections